Standalone Unaudited financial results for the quarter and nine months ended on 31st December, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Jenburkt Pharmaceuticals reported Q3 FY26 revenue from operations of ₹4,302.39 lakhs, up 16.6% year-on-year from ₹3,689.30 lakhs in Q3 FY25, but down 5.6% sequentially from Q2 FY26. Profit after tax for the quarter fell 8.9% YoY to ₹593.14 lakhs (Q3 FY25: ₹650.75 lakhs) and dropped sharply 41.6% QoQ from ₹1,016.34 lakhs, with EPS at ₹13.44 vs ₹14.75 a year ago. For the nine months ended December 2025, revenue grew 12.2% YoY to ₹12,410.83 lakhs and PAT rose modestly 1.5% to ₹2,388.66 lakhs, translating to 9M EPS of ₹54.12. EBITDA margin (PBT + finance + depreciation) compressed sharply from 28.2% in Q3 FY25 to 21.5% in Q3 FY26, mainly due to higher employee and other expenses. The auditor (D.R. Mehta & Associates) issued an unmodified limited review report, and the company noted an additional provision in employee benefits to comply with the new Labour Codes on Wages 2019.
Despite healthy top-line growth, the sharp QoQ drop in profit and YoY EBITDA margin compression signal rising cost pressure, which may temper near-term investor enthusiasm even as full-year revenue is on track to grow.